Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer.

Bruna Pellini Russell W Madison Merrida Childress Shoshana T Miller Ole V Gjoerup Jason Cheng Richard S P Huang Michael Krainock Pratyush Gupta Wei Zou David S Shames Solomon Moshkevich Marcus Ballinger Minetta C Liu Amanda G Young Minu K Srivastava Geoffrey R Oxnard Mark A Socinski

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

ctDNA monitoring during induction chemoIO can inform treatment outcomes in patients with advanced NSCLC. Importantly, monitoring remains feasible and informative for patients missing baseline ctDNA. ctDNA testing during induction chemoIO identifies patients at higher risk for disease progression and may inform patient selection for novel personalized maintenance or second line treatment strategies.

Keyphrases

circulating tumor
advanced non small cell lung cancer
cell free
circulating tumor cells
end stage renal disease
epidermal growth factor receptor
small cell lung cancer
newly diagnosed
ejection fraction
chronic kidney disease
case report
photodynamic therapy
dna methylation
brain metastases